BRPI0914925A2 - peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo - Google Patents

peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo

Info

Publication number
BRPI0914925A2
BRPI0914925A2 BRPI0914925A BRPI0914925A BRPI0914925A2 BR PI0914925 A2 BRPI0914925 A2 BR PI0914925A2 BR PI0914925 A BRPI0914925 A BR PI0914925A BR PI0914925 A BRPI0914925 A BR PI0914925A BR PI0914925 A2 BRPI0914925 A2 BR PI0914925A2
Authority
BR
Brazil
Prior art keywords
peptide
cyclic peptide
diagnosing
antibody
disease
Prior art date
Application number
BRPI0914925A
Other languages
English (en)
Inventor
Gerarda Petronella Johanna Maria Van D Dobbelsteen
Peter Hoogerhout
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of BRPI0914925A2 publication Critical patent/BRPI0914925A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0914925A 2008-07-01 2009-07-01 peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo BRPI0914925A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7726408P 2008-07-01 2008-07-01
EP08159385 2008-07-01
PCT/NL2009/050387 WO2010002251A1 (en) 2008-07-01 2009-07-01 Vaccine against amyloid folding intermediate

Publications (1)

Publication Number Publication Date
BRPI0914925A2 true BRPI0914925A2 (pt) 2015-10-20

Family

ID=39944379

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914925A BRPI0914925A2 (pt) 2008-07-01 2009-07-01 peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo

Country Status (14)

Country Link
US (1) US9045555B2 (pt)
EP (1) EP2297196B1 (pt)
JP (1) JP5722770B2 (pt)
KR (1) KR101694788B1 (pt)
CN (1) CN102112488A (pt)
AU (1) AU2009266552B2 (pt)
BR (1) BRPI0914925A2 (pt)
CA (1) CA2729414C (pt)
ES (1) ES2397641T3 (pt)
IL (1) IL210364A (pt)
MX (1) MX2011000134A (pt)
NZ (1) NZ590324A (pt)
RU (1) RU2546234C2 (pt)
WO (1) WO2010002251A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056510B1 (en) * 2010-03-03 2018-10-03 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2012072611A1 (de) * 2010-11-29 2012-06-07 Philipps-Universität Marburg SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER
TWI571207B (zh) 2011-06-26 2017-02-21 安麗托克斯公司 用於條件化動物飼料之寒冷天氣調配物
EA201491851A1 (ru) * 2011-11-10 2015-12-30 Канджин Ю.С., Инкорпорейтед Композиции и способы для лечения болезни альцгеймера
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
JP2019507581A (ja) * 2015-11-09 2019-03-22 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する立体配座選択的抗体
EP3374380A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia C-TERMINAL EPITOPES IN BETA-AMYLOID AND RELATED CONFORMATIONAL ANTIBODIES
CN108350051A (zh) * 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
KR20180085736A (ko) * 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US20230051538A1 (en) * 2018-10-07 2023-02-16 The University Of British Columbia Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534351A (ja) * 2000-05-22 2003-11-18 ニュー・ヨーク・ユニヴァーシティー アミロイドβ及びアミロイド沈着物に対する免疫応答誘導のための、アミロイドβと相同的な、合成の、免疫原性だが非アミロイド原性ペプチド
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
DK1524994T3 (da) * 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
PL210065B1 (pl) * 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
MX2007013825A (es) * 2005-05-05 2008-01-18 Merck & Co Inc Composiciones de un conjugado peptidico y metodos para la prevencion y tratamiento de la enfermedad de alzheimer.
US20110092445A1 (en) * 2008-07-25 2011-04-21 Abbott Laboratories Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses

Also Published As

Publication number Publication date
AU2009266552A1 (en) 2010-01-07
IL210364A (en) 2016-09-29
MX2011000134A (es) 2011-04-05
JP5722770B2 (ja) 2015-05-27
CA2729414C (en) 2017-08-22
ES2397641T3 (es) 2013-03-08
IL210364A0 (en) 2011-03-31
US20110182928A1 (en) 2011-07-28
CN102112488A (zh) 2011-06-29
AU2009266552B2 (en) 2014-01-23
CA2729414A1 (en) 2010-01-07
EP2297196B1 (en) 2012-11-14
WO2010002251A1 (en) 2010-01-07
KR101694788B1 (ko) 2017-01-13
RU2011103448A (ru) 2012-08-10
RU2546234C2 (ru) 2015-04-10
EP2297196A1 (en) 2011-03-23
KR20110043635A (ko) 2011-04-27
NZ590324A (en) 2012-08-31
JP2011526885A (ja) 2011-10-20
US9045555B2 (en) 2015-06-02

Similar Documents

Publication Publication Date Title
BRPI0914925A2 (pt) peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo
LTPA2017019I1 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9
CY2018003I1 (el) Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
SMT201700102B (it) Anticorpi umani di alta affinitá al recettore attivato dalle proteasi-2 umano
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
LTC2152290I2 (lt) Anti-il-5 antikūnų skyrimo būdai
BRPI0922174A2 (pt) preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BRPI0920250A2 (pt) fixadores internos compósitos
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0912729A2 (pt) válvula de controle do sangue por compressão radial
DK2139987T5 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
BRPI0906849A2 (pt) Dispositivo de iluminação, e, método para prover um estímulo para despertar por meio de um dispositivo de iluminação.
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
BRPI1008145A2 (pt) proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
BRPI0919014A2 (pt) composição fixadora de cabelo, e, uso de uma composição
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]